Table 3.
Phylogeny-trait association test of participant characteristic distribution among people who inject drugs in Vancouver, Canada using BaTS
| Characteristic | Number | Association Index |
|||
|---|---|---|---|---|---|
| Observed (95% CI) | Expected (95% CI) | Ratio | p-value | ||
| Subtype 1a (n=347) | |||||
| Age <27 years (vs. >27 years) | 73 (21%) | 11.0 (9.9, 12.1) | 13.3 (11.7, 14.9) | 0.83 | 0.010 |
| Female (vs. Male) | 82 (24%) | 15.2 (14.1, 16.3) | 14.5 (13.3, 15.9) | 1.05 | 0.750 |
| Inject <3 years (vs. ≥3 years) | 36 (10%) | 7.7 (6.8, 8.6) | 7.4 (6.4, 8.2) | 1.04 | 0.680 |
| ARYS Cohort (vs. VIDUS) | 27 (8%) | 5.1 (4.4, 5.8) | 5.8 (4.9, 6.7) | 0.88 | 0.110 |
| Recent HCV seroconversion (vs. HCV infection at baseline) | 36 (10%) | 6.7 (5.8, 7.6) | 7.3 (6.3, 8.4) | 0.92 | 0.170 |
| HIV co-infection (vs. not) | 92 (27%) | 12.7 (11.5, 13.9) | 15.7 (14.3, 17.2) | 0.81 | 0.010 |
| Subtype 1b (n=44) | |||||
| Age <27 years (vs. >27 years) | 6 (14%) | 1.1 (0.9, 1.4) | 1.1 (0.6, 1.5) | 1.03 | 0.55 |
| Female (vs. Male) | 11 (25%) | 1.5 (1.1, 1.9) | 1.8 (1.2, 2.4) | 0.8 | 0.14 |
| Inject <3 years (vs. ≥3 years) | 6 (14%) | 1.1 (0.9, 1.3) | 1.1 (0.6, 1.5) | 0.95 | 0.43 |
| ARYS Cohort (vs. VIDUS) | 2 (5%) | 0.4 (0.4, 0.5) | 0.4 (0.1, 0.7) | 0.97 | 0.37 |
| Recent HCV seroconversion (vs. HCV infection at baseline) | 2 (5%) | 0.2 (0.1, 0.4) | 0.4 (0.1, 0.7) | 0.49 | 0.08 |
| HIV co-infection (vs. not) | 12 (27%) | 1.6 (1.3, 1.8) | 1.9 (1.2, 2.6) | 0.83 | 0.27 |
| Subtype 2b (n=52) | |||||
| Age <27 years (vs. >27 years) | 8 (15%) | 0.5 (0.4, 0.8) | 1.5 (1.0, 2.0) | 0.36 | <0.001 |
| Female (vs. Male) | 10 (19%) | 2.1 (1.7, 2.4) | 1.8 (1.1, 2.3) | 1.19 | 0.770 |
| Inject <3 years (vs. ≥3 years) | 7 (13%) | 1.5 (1.2, 1.7) | 1.4 (1.0, 1.7) | 1.11 | 0.680 |
| ARYS Cohort (vs. VIDUS) | 3 (6%) | 0.1 (0.1, 0.1) | 0.6 (0.3, 0.9) | 0.09 | <0.001 |
| Recent HCV seroconversion (vs. HCV infection at baseline) | 6 (12%) | 0.8 (0.7, 1.0) | 1.2 (0.7, 1.6) | 0.70 | 0.080 |
| HIV co-infection (vs. not) | 13 (25%) | 2.7 (2.3, 3.2) | 2.1 (1.5, 2.8) | 1.28 | 0.930 |
| Subtype 3a (n=256) | |||||
| Age <27 years (vs. >27 years) | 73 (29%) | 9.2 (8.2, 10.2) | 12.0 (10.6, 13.7) | 0.77 | <0.001 |
| Female (vs. Male) | 76 (30%) | 12.2 (11.1, 13.3) | 12.1 (10.6, 13.8) | 1.00 | 0.570 |
| Inject <3 years (vs. ≥3 years) | 34 (13%) | 7.3 (6.7, 8.1) | 6.7 (5.8, 7.8) | 1.09 | 0.810 |
| ARYS Cohort (vs. VIDUS) | 33 (13%) | 5.1 (4.4, 5.8) | 6.5 (5.8, 7.3) | 0.79 | <0.001 |
| Recent HCV seroconversion (vs. HCV infection at baseline) | 29 (11%) | 5.5 (4.9, 6.1) | 5.9 (5.0, 6.8) | 0.94 | 0.260 |
| HIV co-infection (vs. not) | 48 (19%) | 8.3 (7.4, 9.2) | 8.9 (7.7, 10.1) | 0.94 | 0.210 |
BaTS: Bayesian Tip-association Significance test; CI: Confidence interval; ARYS: At-Risk Youth Study; VIDUS: Vancouver Injection Drug User Study